Show simple item record

dc.contributor.authorRozencweig, M
dc.contributor.authorTen Bokkel Huinink, W
dc.contributor.authorCavalli, F
dc.contributor.authorBruntsch, U
dc.contributor.authorDombernowsky, P
dc.contributor.authorHøst, H
dc.contributor.authorBramwell, Vivien H C
dc.contributor.authorRenard, G
dc.contributor.authorVan Glabbeke, M
dc.contributor.authorDecoster, G
dc.date.accessioned2011-03-03T14:56:56Z
dc.date.available2011-03-03T14:56:56Z
dc.date.issued1984-04
dc.identifier.citationRandomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer. 1984, 2 (4):275-81 J Clin Oncolen
dc.identifier.issn0732-183X
dc.identifier.pmid6584561
dc.identifier.urihttp://hdl.handle.net/10541/123432
dc.description.abstractSixty-three evaluable patients with advanced breast cancer were randomly allocated to receive three-week intravenous courses of carminomycin (18 mg/m2) or 4'-epidoxorubicin (90 mg/m2). The former yielded one (3%) partial response for nine weeks among 29 patients whereas, in the other arm, nine (27%) of 34 patients achieved partial response for a median of 28 weeks (range, nine to 36 weeks; p less than 0.02). The major toxic effect of these anthracyclines was leukopenia with median white blood cell nadirs of 1,600/microL (range, 300-4,000/microL) versus 1,800/microL (range, 500-4,300/microL), respectively. Acute nonhematologic toxic effects were qualitatively similar but carminomycin produced significantly less gastrointestinal intolerance and alopecia. Patients whose disease failed to respond to first-line anthracycline received doxorubicin (60 mg/m2) every three weeks. Four partial responses were obtained among 19 patients previously treated with carminomycin. Following 4'-epidoxorubicin therapy, one of 12 evaluable patients also attained partial response. Survival curves were not affected by the initial treatment option. Carminomycin has marginal activity against breast cancer whereas 4'-epidoxorubicin deserves further evaluation of its therapeutic index relative to doxorubicin. The design used in this trial appears attractive for prompt phase II evaluation of anthracycline analogs.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Metastasisen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAlopecia
dc.subject.meshBreast Neoplasms
dc.subject.meshCarubicin
dc.subject.meshDaunorubicin
dc.subject.meshDoxorubicin
dc.subject.meshDrug Evaluation
dc.subject.meshEpirubicin
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHeart Diseases
dc.subject.meshHumans
dc.subject.meshLeukopenia
dc.subject.meshMiddle Aged
dc.subject.meshNausea
dc.subject.meshNeoplasm Metastasis
dc.subject.meshRandom Allocation
dc.subject.meshVomiting
dc.titleRandomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer.en
dc.typeArticleen
dc.contributor.departmentInstitut Jules Bordet, Brussels, Belgiumen
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractSixty-three evaluable patients with advanced breast cancer were randomly allocated to receive three-week intravenous courses of carminomycin (18 mg/m2) or 4'-epidoxorubicin (90 mg/m2). The former yielded one (3%) partial response for nine weeks among 29 patients whereas, in the other arm, nine (27%) of 34 patients achieved partial response for a median of 28 weeks (range, nine to 36 weeks; p less than 0.02). The major toxic effect of these anthracyclines was leukopenia with median white blood cell nadirs of 1,600/microL (range, 300-4,000/microL) versus 1,800/microL (range, 500-4,300/microL), respectively. Acute nonhematologic toxic effects were qualitatively similar but carminomycin produced significantly less gastrointestinal intolerance and alopecia. Patients whose disease failed to respond to first-line anthracycline received doxorubicin (60 mg/m2) every three weeks. Four partial responses were obtained among 19 patients previously treated with carminomycin. Following 4'-epidoxorubicin therapy, one of 12 evaluable patients also attained partial response. Survival curves were not affected by the initial treatment option. Carminomycin has marginal activity against breast cancer whereas 4'-epidoxorubicin deserves further evaluation of its therapeutic index relative to doxorubicin. The design used in this trial appears attractive for prompt phase II evaluation of anthracycline analogs.


This item appears in the following Collection(s)

Show simple item record